Literature DB >> 27023445

Clinical Utility of Biomarkers in Localized Prostate Cancer.

Michael S Leapman1, Hao G Nguyen2, Matthew R Cooperberg2,3.   

Abstract

A new generation of prostate cancer (PCa) biomarkers has emerged, including diagnostic serum and urine markers aimed at refining the identification high-grade tumors and tissue-based gene expression assays offering prognostic and predictive clinical information. Such tests seek to improve treatment-related decisions at multiple decision points, including initial diagnosis and following initial primary therapy. In this review, we aim to contextualize the body of evidence surrounding these emerging tests, with attention on studies addressing clinical utility.

Entities:  

Keywords:  Biomarkers; Clinical utility; Gene expression tests; Prostate cancer

Mesh：

Substances：

Year:  2016        PMID： 27023445     DOI： 10.1007/s11912-016-0513-1

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  62 in total

1.  Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.

Authors:  Andrew J Vickers; Angel M Cronin; Gunnar Aus; Carl-Gustav Pihl; Charlotte Becker; Kim Pettersson; Peter T Scardino; Jonas Hugosson; Hans Lilja
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

2.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

Authors:  Jack Cuzick; Gregory P Swanson; Gabrielle Fisher; Arthur R Brothman; Daniel M Berney; Julia E Reid; David Mesher; V O Speights; Elzbieta Stankiewicz; Christopher S Foster; Henrik Møller; Peter Scardino; Jorja D Warren; Jimmy Park; Adib Younus; Darl D Flake; Susanne Wagner; Alexander Gutin; Jerry S Lanchbury; Steven Stone
Journal:  Lancet Oncol       Date:  2011-03       Impact factor: 41.316

3.  NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

Authors:  Phillip G Febbo; Marc Ladanyi; Kenneth D Aldape; Angelo M De Marzo; M Elizabeth Hammond; Daniel F Hayes; A John Iafrate; R Kate Kelley; Guido Marcucci; Shuji Ogino; William Pao; Dennis C Sgroi; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2011-11       Impact factor: 11.908

4.  The prostate health index selectively identifies clinically significant prostate cancer.

Authors:  Stacy Loeb; Martin G Sanda; Dennis L Broyles; Sanghyuk S Shin; Chris H Bangma; John T Wei; Alan W Partin; George G Klee; Kevin M Slawin; Leonard S Marks; Ron H N van Schaik; Daniel W Chan; Lori J Sokoll; Amabelle B Cruz; Isaac A Mizrahi; William J Catalona
Journal:  J Urol       Date:  2014-11-15       Impact factor: 7.450

Review 5.  Genomic Predictors of Outcome in Prostate Cancer.

Authors:  Peter J Boström; Anders S Bjartell; James W F Catto; Scott E Eggener; Hans Lilja; Stacy Loeb; Jack Schalken; Thorsten Schlomm; Matthew R Cooperberg
Journal:  Eur Urol       Date:  2015-04-23       Impact factor: 20.096

6.  Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry.

Authors:  E David Crawford; Mark C Scholz; Ashok J Kar; Jeffrey E Fegan; Abebe Haregewoin; Rajesh R Kaldate; Michael K Brawer
Journal:  Curr Med Res Opin       Date:  2014-03-13       Impact factor: 2.580

7.  Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.

Authors:  Massimo Lazzeri; Alexander Haese; Alexandre de la Taille; Joan Palou Redorta; Thomas McNicholas; Giovanni Lughezzani; Vincenzo Scattoni; Vittorio Bini; Massimo Freschi; Amy Sussman; Bijan Ghaleh; Philippe Le Corvoisier; Josep Alberola Bou; Salvador Esquena Fernández; Markus Graefen; Giorgio Guazzoni
Journal:  Eur Urol       Date:  2013-01-24       Impact factor: 20.096

8.  Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.

Authors:  Matthew R Cooperberg; Jeffry P Simko; Janet E Cowan; Julia E Reid; Azita Djalilvand; Satish Bhatnagar; Alexander Gutin; Jerry S Lanchbury; Gregory P Swanson; Steven Stone; Peter R Carroll
Journal:  J Clin Oncol       Date:  2013-03-04       Impact factor: 44.544

9.  Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.

Authors:  Claire de la Calle; Dattatraya Patil; John T Wei; Douglas S Scherr; Lori Sokoll; Daniel W Chan; Javed Siddiqui; Juan Miguel Mosquera; Mark A Rubin; Martin G Sanda
Journal:  J Urol       Date:  2015-01-28       Impact factor: 7.450

10.  A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.

Authors:  Andrew J Vickers; Angel M Cronin; Gunnar Aus; Carl-Gustav Pihl; Charlotte Becker; Kim Pettersson; Peter T Scardino; Jonas Hugosson; Hans Lilja
Journal:  BMC Med       Date:  2008-07-08       Impact factor: 8.775
View more
  9 in total

1.  Prospective evaluation of the role of imaging techniques and TMPRSS2:ERG mutation for the diagnosis of clinically significant prostate cancer.

Authors:  Massimo Lazzeri; Vittorio Fasulo; Giovanni Lughezzani; Alessio Benetti; Giulia Soldà; Rosanna Asselta; Ilaria De Simone; Marco Paciotti; Pier Paolo Avolio; Roberto Contieri; Cesare Saitta; Alberto Saita; Rodolfo Hurle; Giorgio Guazzoni; Nicolò Maria Buffi; Paolo Casale
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738

2.  Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.

Authors:  Matthew R Cooperberg; James D Brooks; Anna V Faino; Lisa F Newcomb; James T Kearns; Peter R Carroll; Atreya Dash; Ruth Etzioni; Michael D Fabrizio; Martin E Gleave; Todd M Morgan; Peter S Nelson; Ian M Thompson; Andrew A Wagner; Daniel W Lin; Yingye Zheng
Journal:  Eur Urol       Date:  2018-02-09       Impact factor: 20.096

Review 3.  The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer.

Authors:  Claire L Tonry; Emma Leacy; Cinzia Raso; Stephen P Finn; John Armstrong; Stephen R Pennington
Journal:  Diagnostics (Basel)       Date:  2016-07-18

Review 4.  Prostate cancer biomarkers: Are we hitting the mark?

Authors:  Shannon McGrath; Daniel Christidis; Marlon Perera; Sung Kyu Hong; Todd Manning; Ian Vela; Nathan Lawrentschuk
Journal:  Prostate Int       Date:  2016-07-29

5.  The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy.

Authors:  Lucy A M Simmons; Abi Kanthabalan; Manit Arya; Tim Briggs; Dean Barratt; Susan C Charman; Alex Freeman; James Gelister; David Hawkes; Yipeng Hu; Charles Jameson; Neil McCartan; Caroline M Moore; Shonit Punwani; Navin Ramachandran; Jan van der Meulen; Mark Emberton; Hashim U Ahmed
Journal:  Br J Cancer       Date:  2017-03-28       Impact factor: 7.640

Review 6.  Active surveillance for intermediate-risk prostate cancer.

Authors:  M A Dall'Era; L Klotz
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-11-01       Impact factor: 5.554

7.  XPNPEP2 is associated with lymph node metastasis in prostate cancer patients.

Authors:  Fei Li; Yun Dai; Hao Xu; Kecheng Huang; Ying Zhou; Danfeng Luo; Ding Ma; Ling Xi; Mengqin Lv; Xiangyi Ma
Journal:  Sci Rep       Date:  2019-07-11       Impact factor: 4.379

8.  SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study.

Authors:  Martina Maggi; Francesco Del Giudice; Ugo G Falagario; Andrea Cocci; Giorgio Ivan Russo; Marina Di Mauro; Giuseppe Salvatore Sepe; Fabio Galasso; Rosario Leonardi; Gabriele Iacona; Peter R Carroll; Matthew R Cooperberg; Angelo Porreca; Matteo Ferro; Giuseppe Lucarelli; Daniela Terracciano; Luigi Cormio; Giuseppe Carrieri; Ettore De Berardinis; Alessandro Sciarra; Gian Maria Busetto
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

9.  Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management.

Authors:  Michael S Leapman; Rong Wang; Henry S Park; James B Yu; Preston C Sprenkle; Michaela A Dinan; Xiaomei Ma; Cary P Gross
Journal:  JAMA Netw Open       Date:  2021-10-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.